Precision Biosciences Inc Quick Ratio (DTIL) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Precision Biosciences Inc  (NASDAQ: DTIL)

Precision Biosciences Inc's Quick Ratio

DTIL's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 2.19 below Precision Biosciences Inc average.

Within Biotechnology & Pharmaceuticals industry 86 other companies have achieved higher Quick Ratio than Precision Biosciences Inc in second quarter 2026. While Quick Ratio total ranking has improved so far during the Q2 2026 to 373, from total ranking in the first quarter 2026 at 442.

Explain Quick Ratio?
How much Cash & cash equivalents DTIL´s has?
What are DTIL´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

DTIL Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change 193.97 % -37.42 % -40.5 % 25.15 % -58.83 %
Y / Y Cash & cash equivalent Change 40.66 % 31.03 % 33.92 % -55.66 % -49.63 %
Quick Ratio MRQ 2.19 13.05 12.97 2.99 4.59
DTIL's Total Ranking # 373 # 442 # 1233 # 950 # 787
Seq. Current Liabilities Change 414.33 % -12.99 % -40.56 % 10.52 % 9.48 %
Seq. Cash & cash equivalent Change -13.48 % -12.46 % 157.6 % -27.91 % -19.4 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 87
Healthcare Sector # 481
Overall Market # 1330


Quick Ratio Statistics
High Average Low
14.29 5.11 1.63
(Jun 30 2019)   (Mar 31 2019)




Financial Statements
Precision Biosciences Inc's Current Liabilities $ 40 Millions Visit DTIL's Balance sheet
Precision Biosciences Inc's Cash & cash equivalent $ 88 Millions Visit DTIL's Balance sheet
Source of DTIL's Sales Visit DTIL's Sales by Geography


Cumulative Precision Biosciences Inc's Quick Ratio

DTIL's Quick Ratio for the trailling 12 Months

DTIL Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 35.2 % -37.45 % -46.52 % -56.39 % -68.29 %
Y / Y Cash & cash equivalent TTM Growth 6.79 % -16.59 % -33.18 % -43.52 % -34.64 %
Quick Ratio TTM 4.88 7.16 6.01 4.84 6.18
Total Ranking TTM # 201 # 280 # 231 # 170 # 212
Seq. Current Liabilities TTM Growth 58.18 % -9.3 % -10.85 % 5.7 % -26.81 %
Seq. Cash & cash equivalent TTM Growth 7.81 % 7.99 % 10.82 % -17.23 % -15.79 %

Quick ratio ranking by company, industry and sector >> Back to DTIL Financial Strength Comparisons >> Go to Compare DTIL Quick Ratio to its Competitors

On the trailing twelve months basis Due to in Current Liabilities in the Q2 2026 to $39.89 millions, cumulative Quick Ratio decreased to 4.88 above the DTIL average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 138 other companies have achieved higher Quick Ratio than Precision Biosciences Inc. While Quick Ratio overall ranking has improved so far to 0, from total ranking during the twelve months ending first quarter 2026 at 3497.

Explain Quick Ratio?
How much Cash & cash equivalents DTIL´s has?
What are DTIL´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 139
Healthcare Sector # 847
Within the Market # 373


trailing twelve months Quick Ratio Statistics
High Average Low
8.79 4.31 0.56
(Jun 30 2026)   (Mar 31 2019)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Biotechnology & Pharmaceuticals Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Repligen Corp  5.94 $ 810.449  Millions$ 136.403  Millions
Cabaletta Bio Inc   5.64 $ 225.101  Millions$ 39.910  Millions
Revolution Medicines Inc   5.54 $ 3,937.969  Millions$ 710.589  Millions
Humacyte Inc   5.35 $ 79.903  Millions$ 14.948  Millions
Invivyd Inc   5.16 $ 160.080  Millions$ 31.028  Millions
Lineage Cell Therapeutics Inc   5.13 $ 50.855  Millions$ 9.914  Millions
Alector Inc   5.05 $ 172.798  Millions$ 34.236  Millions
Atyr Pharma Inc   5.04 $ 57.418  Millions$ 11.396  Millions
Vericel Corporation  5.04 $ 264.531  Millions$ 52.532  Millions
Inhibrx Biosciences Inc   4.75 $ 133.344  Millions$ 28.064  Millions
Replimune Group Inc   4.57 $ 195.328  Millions$ 42.767  Millions
Recursion Pharmaceuticals Inc   4.55 $ 545.683  Millions$ 119.886  Millions
Prime Medicine Inc   4.50 $ 142.720  Millions$ 31.692  Millions
Immunitybio inc   4.50 $ 357.371  Millions$ 79.392  Millions
Dbv Technologies S a   4.37 $ 174.900  Millions$ 40.000  Millions
Metagenomi Therapeutics Inc   4.37 $ 120.700  Millions$ 27.632  Millions
Alpha Cognition Inc.  4.37 $ 41.443  Millions$ 9.493  Millions
Intensity Therapeutics Inc   4.23 $ 9.500  Millions$ 2.245  Millions
Ginkgo Bioworks Holdings Inc   4.15 $ 302.163  Millions$ 72.740  Millions
Dyadic International Inc   4.13 $ 16.047  Millions$ 3.883  Millions
Tenaya Therapeutics Inc   4.11 $ 78.100  Millions$ 19.021  Millions
Vir Biotechnology Inc   4.08 $ 530.522  Millions$ 130.177  Millions
Adaptive Biotechnologies Corporation  3.92 $ 344.255  Millions$ 87.712  Millions
Immunocore Holdings Plc  3.74 $ 880.211  Millions$ 235.198  Millions
Entera Bio Ltd   3.50 $ 11.309  Millions$ 3.235  Millions
Exozymes Inc   3.49 $ 5.653  Millions$ 1.618  Millions
Acumen Pharmaceuticals Inc   3.44 $ 160.954  Millions$ 46.848  Millions
Century Therapeutics inc   3.29 $ 49.642  Millions$ 15.068  Millions
Adma Biologics Inc   3.26 $ 136.020  Millions$ 41.690  Millions
Tscan Therapeutics Inc   3.23 $ 100.156  Millions$ 30.964  Millions

Date modified: 2026-09-26T07:36:46+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.